Lab
Knoxville Dermatopathology Laboratory LLC
Knoxville Dermatopathology Laboratory LLC was paid $942K by Medicaid between Jan 2018 and Aug 2023, across 42 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 29% of everything it billed.
33Billing provider infoKNOXVILLE DERMATOPATHOLOGY LABORATORY LLC
PLANO, TX 75024
PLANO, TX 75024
33aNPI1619974573assigned 07/06/2005
33bProvider typeClinical Medical Laboratory
28Total paid$942K
24GClaims51,449
24DCodes billed42
24AFirst – last monthJan 2018 – Aug 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#71 of 436
Median peer was paid$17K
This provider vs. median55×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,634 | $21K | |
| 2019 | 1,845 | $23K | |
| 2020 | 2,426 | $22K | |
| 2021 | 6,786 | $128K | |
| 2022 | 32,169 | $538K | |
| 2023 | 5,589 | $209K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 29% | 3,732 | 3,142 | $269K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 8.2% | 745 | 659 | $78K |
| 87900 | 7.6% | 2,125 | 1,804 | $71K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 6.7% | 7,241 | 5,109 | $63K |
| 88377 | 5.1% | 382 | 344 | $48K | |
| 88120 | 4.1% | 316 | 264 | $39K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.8% | 1,925 | 1,728 | $35K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.3% | 1,057 | 672 | $31K |
| 87481 | 2.9% | 2,499 | 2,044 | $27K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 2.7% | 426 | 282 | $25K |
| 87653 | 2.5% | 2,841 | 2,359 | $24K | |
| 87641 | 2.5% | 2,261 | 2,024 | $23K |
30 more codes
| 87529 | 2.3% | 1,755 | $21K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1.7% | 554 | $16K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.7% | 1,357 | $16K |
| 87500 | 1.6% | 2,795 | $15K | |
| 88342 | 1.5% | 1,231 | $14K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.5% | 2,316 | $14K |
| 88312 | 1.5% | 1,018 | $14K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.4% | 2,368 | $13K |
| 87581 | 1.3% | 746 | $12K | |
| 87486 | 1.3% | 741 | $12K | |
| 87541 | 1.3% | 739 | $12K | |
| 87563 | 1.3% | 2,768 | $12K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 153 | $5K |
| 0500T | <1% | 593 | $4K | |
| 87511 | <1% | 2,365 | $4K | |
| 87625 | <1% | 152 | $4K | |
| 88142 | <1% | 555 | $4K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 46 | $2K |
| 88104 | <1% | 299 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,061 | $2K |
| 88341 | <1% | 104 | $2K | |
| 88108 | <1% | 244 | $2K | |
| 87551 | <1% | 215 | $1K | |
| 87561 | <1% | 214 | $1K | |
| 87556 | <1% | 193 | $982.94 | |
| 87496 | <1% | 115 | $576.68 | |
| 88143 | <1% | 40 | $198.96 | |
| 88313 | <1% | 24 | $83.22 | |
| 85060 | <1% | 99 | $20.78 | |
| 88300 | <1% | 39 | $15.86 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialINGRAM, MARC (CEO)
| Provider | Location | Paid |
|---|---|---|
| Convergent Diagnostics, LLC | Allen, TX | $3.18M |
| Firstpath Laboratory Services LLC | Pompano Beach, FL | $174K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.